Last reviewed · How we verify
Regimen:TDF+3TC+EFV
This combination regimen inhibits HIV reverse transcriptase and integrase through three antiretroviral agents, preventing viral replication and reducing viral load.
This combination regimen inhibits HIV reverse transcriptase and integrase through three antiretroviral agents, preventing viral replication and reducing viral load. Used for HIV-1 infection (treatment).
At a glance
| Generic name | Regimen:TDF+3TC+EFV |
|---|---|
| Sponsor | National Center for AIDS/STD Control and Prevention, China CDC |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
TDF (tenofovir disoproxil fumarate) and 3TC (lamivudine) are nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase, while EFV (efavirenz) is a non-nucleoside reverse transcriptase inhibitor that also targets the same enzyme through a different mechanism. Together, these three agents suppress HIV replication by preventing the conversion of viral RNA to DNA and integration into the host genome.
Approved indications
- HIV-1 infection (treatment)
Common side effects
- Neuropsychiatric effects (dizziness, impaired concentration, abnormal dreams)
- Rash
- Nausea
- Headache
- Elevated liver enzymes
- Renal dysfunction (TDF-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: